Logo image of FLGT

FULGENT GENETICS INC (FLGT) Stock Fundamental Analysis

NASDAQ:FLGT - Nasdaq - US3596641098 - Common Stock - Currency: USD

16.46  -0.17 (-1.02%)

After market: 16.46 0 (0%)

Fundamental Rating

4

Taking everything into account, FLGT scores 4 out of 10 in our fundamental rating. FLGT was compared to 108 industry peers in the Health Care Providers & Services industry. FLGT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. FLGT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year FLGT was profitable.
FLGT had a positive operating cash flow in the past year.
In multiple years FLGT reported negative net income over the last 5 years.
Each year in the past 5 years FLGT had a positive operating cash flow.
FLGT Yearly Net Income VS EBIT VS OCF VS FCFFLGT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M

1.2 Ratios

With a Return On Assets value of -13.37%, FLGT is not doing good in the industry: 73.83% of the companies in the same industry are doing better.
The Return On Equity of FLGT (-14.49%) is worse than 61.68% of its industry peers.
Industry RankSector Rank
ROA -13.37%
ROE -14.49%
ROIC N/A
ROA(3y)12.15%
ROA(5y)13.32%
ROE(3y)13.45%
ROE(5y)15.5%
ROIC(3y)N/A
ROIC(5y)N/A
FLGT Yearly ROA, ROE, ROICFLGT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150

1.3 Margins

FLGT has a better Gross Margin (36.22%) than 63.55% of its industry peers.
In the last couple of years the Gross Margin of FLGT has declined.
FLGT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 36.22%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-22.87%
GM growth 5Y-6.3%
FLGT Yearly Profit, Operating, Gross MarginsFLGT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50

More info and screens

6

2. Health

2.1 Basic Checks

FLGT does not have a ROIC to compare to the WACC, probably because it is not profitable.
FLGT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, FLGT has more shares outstanding
Compared to 1 year ago, FLGT has an improved debt to assets ratio.
FLGT Yearly Shares OutstandingFLGT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
FLGT Yearly Total Debt VS Total AssetsFLGT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

2.2 Solvency

FLGT has an Altman-Z score of 4.08. This indicates that FLGT is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 4.08, FLGT is doing good in the industry, outperforming 79.44% of the companies in the same industry.
FLGT has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
FLGT has a Debt to Equity ratio of 0.00. This is amongst the best in the industry. FLGT outperforms 86.92% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.08
ROIC/WACCN/A
WACC8.95%
FLGT Yearly LT Debt VS Equity VS FCFFLGT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M 800M 1B

2.3 Liquidity

FLGT has a Current Ratio of 4.41. This indicates that FLGT is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 4.41, FLGT belongs to the best of the industry, outperforming 92.52% of the companies in the same industry.
A Quick Ratio of 4.41 indicates that FLGT has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.41, FLGT belongs to the top of the industry, outperforming 92.52% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.41
Quick Ratio 4.41
FLGT Yearly Current Assets VS Current LiabilitesFLGT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

FLGT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 162.39%, which is quite impressive.
Looking at the last year, FLGT shows a decrease in Revenue. The Revenue has decreased by -3.05% in the last year.
FLGT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 68.33% yearly.
EPS 1Y (TTM)162.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%179.49%
Revenue 1Y (TTM)-3.05%
Revenue growth 3Y-11.81%
Revenue growth 5Y68.33%
Sales Q2Q%-15.28%

3.2 Future

Based on estimates for the next years, FLGT will show a very strong growth in Earnings Per Share. The EPS will grow by 27.37% on average per year.
The Revenue is expected to grow by 9.13% on average over the next years. This is quite good.
EPS Next Y181.27%
EPS Next 2Y4.5%
EPS Next 3Y27.37%
EPS Next 5YN/A
Revenue Next Year-0.58%
Revenue Next 2Y7.39%
Revenue Next 3Y9.13%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
FLGT Yearly Revenue VS EstimatesFLGT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 200M 400M 600M 800M
FLGT Yearly EPS VS EstimatesFLGT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 5 10 15

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 22.55, FLGT is valued on the expensive side.
66.36% of the companies in the same industry are more expensive than FLGT, based on the Price/Earnings ratio.
FLGT's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 29.62.
FLGT is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 22.55
Fwd PE N/A
FLGT Price Earnings VS Forward Price EarningsFLGT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FLGT Per share dataFLGT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

FLGT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as FLGT's earnings are expected to grow with 27.37% in the coming years.
PEG (NY)0.12
PEG (5Y)N/A
EPS Next 2Y4.5%
EPS Next 3Y27.37%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FLGT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FULGENT GENETICS INC

NASDAQ:FLGT (2/21/2025, 8:18:35 PM)

After market: 16.46 0 (0%)

16.46

-0.17 (-1.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-08 2024-11-08/bmo
Earnings (Next)02-28 2025-02-28/bmo
Inst Owners57.12%
Inst Owner Change-94.26%
Ins Owners32.27%
Ins Owner Change-0.74%
Market Cap503.51M
Analysts77.78
Price Target26.86 (63.18%)
Short Float %5.05%
Short Ratio4.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)223.62%
Min EPS beat(2)149.02%
Max EPS beat(2)298.21%
EPS beat(4)4
Avg EPS beat(4)184.98%
Min EPS beat(4)96.94%
Max EPS beat(4)298.21%
EPS beat(8)7
Avg EPS beat(8)108.19%
EPS beat(12)11
Avg EPS beat(12)117.61%
EPS beat(16)14
Avg EPS beat(16)92.42%
Revenue beat(2)1
Avg Revenue beat(2)-0.55%
Min Revenue beat(2)-1.93%
Max Revenue beat(2)0.82%
Revenue beat(4)2
Avg Revenue beat(4)-0.04%
Min Revenue beat(4)-3.28%
Max Revenue beat(4)4.22%
Revenue beat(8)6
Avg Revenue beat(8)7.09%
Revenue beat(12)10
Avg Revenue beat(12)9.61%
Revenue beat(16)12
Avg Revenue beat(16)8.18%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)183.05%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.43%
Valuation
Industry RankSector Rank
PE 22.55
Fwd PE N/A
P/S 1.81
P/FCF N/A
P/OCF 46
P/B 0.44
P/tB 0.51
EV/EBITDA N/A
EPS(TTM)0.73
EY4.43%
EPS(NY)-0.37
Fwd EYN/A
FCF(TTM)-0.94
FCFYN/A
OCF(TTM)0.36
OCFY2.17%
SpS9.08
BVpS37.22
TBVpS32.01
PEG (NY)0.12
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.37%
ROE -14.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 36.22%
FCFM N/A
ROA(3y)12.15%
ROA(5y)13.32%
ROE(3y)13.45%
ROE(5y)15.5%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-22.87%
GM growth 5Y-6.3%
F-Score6
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 156.83%
Cap/Sales 14.27%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.41
Quick Ratio 4.41
Altman-Z 4.08
F-Score6
WACC8.95%
ROIC/WACCN/A
Cap/Depr(3y)119.6%
Cap/Depr(5y)317.19%
Cap/Sales(3y)4.37%
Cap/Sales(5y)5.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)162.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%179.49%
EPS Next Y181.27%
EPS Next 2Y4.5%
EPS Next 3Y27.37%
EPS Next 5YN/A
Revenue 1Y (TTM)-3.05%
Revenue growth 3Y-11.81%
Revenue growth 5Y68.33%
Sales Q2Q%-15.28%
Revenue Next Year-0.58%
Revenue Next 2Y7.39%
Revenue Next 3Y9.13%
Revenue Next 5YN/A
EBIT growth 1Y-9.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year84.4%
EBIT Next 3Y30.15%
EBIT Next 5YN/A
FCF growth 1Y-110.35%
FCF growth 3Y-64.31%
FCF growth 5YN/A
OCF growth 1Y-96.32%
OCF growth 3Y-42.3%
OCF growth 5YN/A